Desloratadine
| Clinical data | |
|---|---|
| Trade names | Aerius, others | 
| Other names | Descarboethoxyloratadine | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a602002 | 
| License data | |
| Pregnancy category | 
 | 
| Routes of administration | By mouth | 
| Drug class | Second-generation antihistamine | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Rapidly absorbed | 
| Protein binding | 83–87% | 
| Metabolism | UGT2B10, CYP2C8 | 
| Metabolites | 3-Hydroxydesloratadine | 
| Onset of action | within 1 hour | 
| Elimination half-life | 27 hours, 33.7 hours in elderly patients | 
| Duration of action | up to 24 hours | 
| Excretion | 40% as conjugated metabolites into urine Similar amount into the feces | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.166.554 | 
| Chemical and physical data | |
| Formula | C19H19ClN2 | 
| Molar mass | 310.83 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.
It was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.